Goldman Sachs Group set a €92.00 ($106.98) price target on Merck KGaA (FRA:MRK) in a report published on Monday morning. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other research firms have also recently weighed in on MRK. Barclays set a €70.00 ($81.40) price target on Merck KGaA and gave the stock a sell rating in a report on Friday, August 24th. Warburg Research set a €100.00 ($116.28) price target on Merck KGaA and gave the stock a neutral rating in a report on Tuesday, August 28th. Berenberg Bank set a €102.00 ($118.60) price target on Merck KGaA and gave the stock a buy rating in a report on Thursday, August 30th. Credit Suisse Group set a €93.00 ($108.14) price target on Merck KGaA and gave the stock a neutral rating in a report on Wednesday, August 8th. Finally, Societe Generale set a €92.00 ($106.98) price target on Merck KGaA and gave the stock a neutral rating in a report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company. The company has an average rating of Hold and an average target price of €98.71 ($114.78).

FRA MRK opened at €86.94 ($101.09) on Monday. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Article: Understanding Relative Strength Index

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.